Important Product Safety Information

• Optimark™ Gadoversetamide injection
  Click on product to view warning

News & Press

• Archive

• Please note important safety updates for Optimark™ (gadoversetamide injection), effective November 6, 2009.

  Click here for 11/6/09 updated boxed warning and important safety information

  Click here for 11/6/09 Optimark DHCP letter

  All barium products and accessories will be discontinued effective January 15, 2010. Please see the attached customer letter for details regarding the discontinuation of these products.

  Customer Letter

  Covidien Responds to Molybdenum 99 Supply Shortage

  Click here for current information www.covidien.com/Mo99supply

• 11/9/2009 8:02:00 AM

  Covidien Submits Label Change for Optimark(TM) Contrast Agent

  New Label Contraindicates Product for Use in Patients with Severe Renal Impairment ST. LOUIS--(BUSINESS WIRE)--Nov. 9, 2009-- Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it will voluntarily contraindicate the use of its Optimark™ gadoversetami…

• 11/17/2009 6:01:00 AM

  Covidien Reports Fourth-Quarter and Fiscal 2009 Results

  Fourth-quarter diluted GAAP earnings per share from continuing operations were $0.11; excluding specified items, adjusted diluted earnings per share from continuing operations were $0.72 Fiscal 2009 diluted GAAP earnings per share from continuing operations were …

• 11/4/2009 7:01:00 AM

  Covidien to Present at Credit Suisse Healthcare Conference

  MANSFIELD, Mass.--(BUSINESS WIRE)--Nov. 4, 2009-- Covidien (NYSE: COV) will present at the Credit Suisse 18th Annual Healthcare Conference in Phoenix on Wednesday, November 11, 2009. Charles J. Dockendorff, Executive Vice President and Chief Financial …